No Photo Available

Last Update


This profile was last updated on .

Is this you? Claim your profile.

Wrong Giovanni Migliori?

Dr. Giovanni Battista Migliori


WHO Collaborating Centre for TB and Lung Diseases

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

WHO Collaborating Centre for TB and Lung Diseases

Background Information

Employment History

Associate Editor

International Journal of Tuberculosis

Teaching Professor

School of Specialization


Royal College of Physicians

Secretary General
European Respiratory Society


Medical Statistics

University of Pavia


Web References (53 Total References)

Prof. Giovanni Battista ... [cached]

Prof. Giovanni Battista Migliori, MD, FRCP, FERS Director, WHO Collaborating Centre for TB and Lung Diseases

Prof. Giovanni Battista ... [cached]

Prof. Giovanni Battista Migliori, MD, FRCP, FERS Director, WHO Collaborating Centre for TB and Lung Diseases

And those are eight main areas," ... [cached]

And those are eight main areas," says Giovanni Batista Migliori, head of the European Respiratory Society and director of the WHO Collaborating Center for Tuberculosis and Lung Diseases.

Migliori says the eight key interventions include increased funding to screen for active and silent TB infection in high risk groups, such as people with HIV, residents of impoverished communities and migrants from neighboring countries.
In addition, he says the governments should invest in research into new tools to rapidly identify and treat tuberculosis, including multi-drug resistant strains.
Migliori says there's a strong motivation for low-burden countries to try to eliminate TB.
"There are several studies showing that the treatment and prevention of tuberculosis is cost-effective. So, that the society costs due to tuberculosis are much higher than the investment needed to prevent them [the disease]," he said.
Migliori says a renewed push to eliminate TB is needed so a resurgence of a preventable and treatable disease does not occur in low-burden countries.

Extensively drug-resistant tuberculosis: Back to the pre-antibiotic era? | [cached]

"TB is a global problem that needs to be dealt with by the international community," urges Professor Giovanni Battista Migliori, ERS Assembly Head Respiratory Infections and Director of the WHO Collaborating Centre for TB and Lung Disease, Tradate, Italy.

"These cases are offered the limited treatment weapons available in the pre-antibiotic era; that is, good food, fresh air and, perhaps artificial pneumothorax", write Professor Migliori and colleagues.

And, according to Prof. Giovanni ... [cached]

And, according to Prof. Giovanni Battista Migliori, head of ERS Assembly 10 'Respiratory Infections', more and more cases resistant to almost all drugs are reported in western Europe, often among migrants come from the former Soviet Union. These cases absorb significant resources for treatment-more than €150,000 per case-with a probability of success often below 50%.

"XDR is at present a major threat to TB control, and too many patients are still dying of it," says Prof. Migliori, who is Director of the WHO Collaborating Centre for TB and Lung Diseases of the Fondazione S. Maugeri, Care and Research Institute in Tradate, Italy. "Of course we need new drugs and better diagnostics, but we need first of all to prevent its emergence by treating and curing adequately all the susceptible cases."
Hot topics
He adds that WHO issued new recommendations in September on new diagnostics for TB and MDR-TB, soon to be captured in updated guidelines. These, according to Prof. Migliori, constitute one of the hot topics under discussion in the field, along with the future location of new molecular methods in diagnostic algorithms and the optimal duration of intensive and continuation phase of treatment.
"The debate is between, on the one hand, developing new diagnostics and drugs to treat the disease, on the other preventing its emergence through stronger TB programmes and heath systems," stresses Prof. Migliori, referring to a much-quoted editorial* published in the March 2007 edition of the European Respiratory Journal.
The new CME online module features panel discussion of the issue between Prof. Migliori and Prof. Christophe Lange, of the Medizinische Klinik in Borstel (Germany) and chair of ERS group 10.2 'Tuberculosis'.
"The new module systematically presents the evidence available and shows the research contribution to better shed light on this alarming clinical and public health problem," says Prof. Migliori. "ERS hopes that it will further enhance the visibility of TBNET and its capacity to support the MDR-TB activities performed directly by Assembly 10," he concludes.

Similar Profiles

Other People with this Name

Other people with the name Migliori

Richard Migliori

Joan Migliori
Promontory Financial Group LLC

Cynthia Migliori
Southern New Hampshire University

Fabrizio Migliori
E-servizi S.p.a.

Alberto Migliori
Gullivers Travel Associates

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory